The Long Run with Luke Timmerman
- Episodios
- 211
- Se publica
- cada dos semanas
- Último episodio
- 3 Nov 2026
Sobre el podcast
"The Long Run" Antarctic explorer Ernest Shackleton would appreciate today's biotech. Scientific entrepreneurs of the 21st century must be ready for what Shackleton called the “hazardous journey, bitter cold, long months of complete darkness, constant danger, safe return doubtful, honor and recognition in case of success.” Today, the men and women who strive to apply science for the betterment of human health have a historic opportunity. They need stamina and resilience to achieve something meaningful. Biotech’s relationship with the society that sustains it has never been more tenuous. Join host Luke Timmerman for in-depth, thought-provoking conversations with biotech newsmakers pursuing these great opportunities of the 21st century.
Episodios 211
Ep213: Daphne Koller on The Moment in AI Drug Discovery
Daphne Koller, founder and CEO of South San Francisco-based Insitro, on the moment in AI drug discovery.
Ep212: Tim Shannon on Creating Targeted Protein Degraders as Medicines
Tim Shannon is a general partner at Canaan Partners, and a founding executive at a pair of targeted protein degrader companies -- Arvinas and Halda Therapeutics.
Ep211: Ardem Patapoutian on Touch, Pain & New Discoveries in Neuroscience
Arden Patapoutian, professor of neuroscience at Scripps Research and Howard Hughes Medical Institute, on new discoveries in neuroscience related to our sense of touch, pain, and more.
Ep210: Cameron Turtle on Long-Lasting Antibodies for Immune Disorders
Cameron Turtle, CEO of Waltham, Mass.-based Spyre Therapeutics, on developing long-lasting antibodies for immune disorders.
Ep209: Mathai Mammen on Developing Drugs Against Undruggable Targets
Mathai Mammen, CEO of Cambridge, Mass.-based Parabilis Medicine, on developing alpha helical peptide molecules against hard targets of disease.
Ep208: Gary Nabel on Developing a Vaccine for Epstein-Barr Virus
Gary Nabel, CEO of Weston, Mass.-based ModeX Therapeutics, on developing a vaccine for Epstein-Barr Virus.
Ep207: Jason Coloma on Genetic Medicines for Kidney Diseases
Jason Coloma, CEO of South San Francisco-based Maze Therapeutics, on developing small molecule drugs based on human genetics for kidney diseases.
Ep206: Lyn Baranowski on Inhalable Medicines for Severe Lung Diseases
Lyn Baranowski, CEO of Boston-based Avalyn Pharma, on developing inhalable medicines for severe lung diseases.
Ep205: Heather Turner on a Schizophrenia Drug Patients Can Stick With
Heather Turner, CEO of New York-based LB Pharma, on developing a new schizophrenia drug designed to better cross the blood-brain barrier, be dosed once daily, and make it easier for patients to take long term.
Ep204: Troy Wilson on Precision Cancer Drugs and Combos
Troy Wilson, CEO of San Diego-based Kura Oncology, on his career in biotech and developing targeted cancer drugs.
Ep203: Sri Kosuri on Small Molecule Correctors of Disease
Sri Kosuri, co-founder and CEO of Emeryville, Calif.-based Octant Bio, on small molecules designed to correct protein misfolding and mistrafficking at the root of many diseases.
Ep202: Becky Pferdehirt on Reimagining Science for the AI Era
Becky Pferdehirt, CEO of Emeryville, CA-based Radial, the life sciences unit of Astera Institute, on reimagining biology to take advantage of advances in AI.
Ep201: Jeremy Levin on Biotech in the Balance
Jeremy Levin, executive chair of Ovid Therapeutics, discusses his new book "Biotech in the Balance: Saving a Strategic Industry in an Age of Distrust."
Ep200: Richard Pops Reflects on a 35-Year Career in Biotech
Alkermes CEO Richard Pops reflects on his 35-year career leading the company and its new opportunity in orexin biology for sleep disorders and more neurological conditions.
Ep199: Martin Burke on Making Small Molecule Medicines for the AI Era
Marty Burke, a professor of chemistry at the University of Illinois and co-founder of Excelsior Sciences, on making small molecule synthesis more automated for AI.
Ep198: Abbas Kazimi on Computation and Culture for Drug Discovery
Abbas Kazimi, CEO of Boston-based Nimbus Therapeutics, on computation and culture for drug discovery.
Ep197: Viswa Colluru on Discovering Drugs Inspired by Mother Nature
Viswa Colluru, founder and CEO of Boulder, Colo.-based Enveda, on drug discovery with a chemistry platform inspired by natural products.
Ep196: Otello Stampacchia on Europe's Biotech Crisis
Otello Stampacchia, founder and managing director of Omega Funds, on attempting to reform Europe's biotech investment climate.
Ep195: Ken Song on T-cell Engagers for Autoimmune Diseases
Ken Song, CEO of San Diego-based Candid Therapeutics, on developing bispecific T-cell engaging antibodies for autoimmune disease.
Ep194: Ansu Satpathy on Cancer and Autoimmune Drug Discovery
Ep194: Ansu Satpathy on Cancer and Autoimmune Drug Discovery by Timmerman Report
Ep193: Ron Renaud on Helping People Lose Weight With GLP-1 Medicines
Ron Renaud, CEO of Waltham, Mass.-based Kailera Therapeutics, on developing GLP-1 based medicines to help people lose weight and live healthier lives.
Ep192: Kate Haviland on Following the Science to Precision Immunology
Kate Haviland, former CEO of Blueprint Medicines, on how the company transitioned to a precision immunology company and was acquired by Sanofi for $9.5 billion.
Ep191: Emily Conley on Small Molecules to Correct a Rare Kidney Disease
Emily Conley, CEO of Berkeley, CA-based Renasant Bio, on developing small molecule correctors and potentiators for autosomal dominant polycystic kidney disease (ADPKD).
Ep190: Neil Kumar on Building a Rare Disease Drug Company
Neil Kumar is founder and CEO of Palo Alto, Calif.-based BridgeBio Pharma, a rare disease drug developer.
Ep189: Marc Tessier-Lavigne on Reinventing Drug Discovery with AI
Marc Tessier-Lavigne, CEO of South San Francisco-based Xaira Therapeutics, on reinventing drug discovery with AI.
Ep188: Art Krieg on Innate Immune System Activators for Cancer
Art Krieg, founder and CEO of Zola Therapeutics, on developing innate immune system activators for cancer.
Ep187: Eric Fischer on Creating a New Class of Medicines
Eric Fischer, a professor at Dana-Farber Cancer Institute, on creating a new class medicines -- targeted protein degraders.
Ep186: Bruce Levine & Mags McCarthy on a Song About Science and Hope
Bruce Levine, a CAR-T cell therapy researcher at the University of Pennsylvania, and Mags McCarthy, a country music star, discuss their new song about science and hope for cancer patients.
Ep185: Dr. Lachelle Weeks on Predicting Leukemia Risk At Scale
Dr. Lachelle Weeks is a physician-scientist at Dana-Farber Cancer Institute working on a project to predict leukemia risk based on widely available blood samples.
Ep184: Jen Adair on Affordable, Accessible Gene & Cell Therapies
Jen Adair, professor and associate director of the Horae Gene Therapy Center at the University of Massachusetts Chan Medical School, on creating more affordable and accessible cell and gene therapies.
Aquí están los 40 episodios más recientes de 211. Los anteriores están en el feed del podcast.
Podcasts similares
Más podcasts de Ciencias
¿Es tu podcast?
Confírmalo con una entrada en tu feed: aquí recibes un código, lo añades como podcast:txt en el canal de tu feed y nosotros lo comprobamos. Después tu podcast aparecerá como «verificado» en SoundNode.